Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis®
- Jonathan I. Silverberg
- , Marjolein de Bruin-Weller
- , Brian M. Calimlim
- , Xiaofei Hu
- , Sarah A. Ofori
- , Andrew M. Platt
- , Henrique D. Teixeira
- , Kilian Eyerich
- , Jacob P. Thyssen
- George Washington School of Medicine and Health Sciences
- Department of Dermatology and Allergology
- AbbVie
- Albert-Ludwigs-Universität Freiburg
- Frederiksberg and Bispebjerg Hospital
Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung
1
Zitat
(Scopus)